Leading US hospital systems founded Civica [1] in 2018, to reduce chronic generic drug shortages in the US. It is a non-profit, non-stock corporation committed to stabilizing the supply of essential generic medications in hospitals. More than 30 health systems are Civica members and it currently represents approximately 30 per cent of all licensed US hospital beds.

The new agreement with Hikma, the third largest supplier of generic injectable medicines in the US, recognizes Hikma’s ability to deliver a large and consistent supply of quality injectable medicines. It will also take advantage of the significant investments made to expand their manufacturing capacity and capabilities. In recent years, the company has played a key role in launching medications to reduce drug shortages and in 2016 the company received a Drug Shortage Assistance Award from the US Food and Drug Administration for its role in preventing or alleviating drug shortages.

The five-year commitment from Civica guarantees demand and fair and sustainable pricing of the generic drug products. This will support Hikma and allow for effective production planning and more long-term manufacturing investments.

Related articles
Hikma launches HIV generic ritonavir in the US

Biosimilar deals for Hikma and Lupin

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Hospitals launch non-profit generics company [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Aug 23]. Available from: www.gabionline.net/Generics/General/Hospitals-launch-non-profit-generics-company

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.